These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6831748)

  • 1. Pharmacokinetics of triamterene.
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Clin Exp Hypertens A; 1983; 5(2):249-69. PubMed ID: 6831748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetics of triamterene in healthy subjects and patients with liver and kidney function disorders].
    Mutschler E; Gilfrich HJ; Knauf H; Möhrke W; Völger KD
    Klin Wochenschr; 1983 Sep; 61(18):883-91. PubMed ID: 6632729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacokinetics of triamterene and its active metabolites in renal insufficiency (author's transl)].
    Grebian B; Geissler HE; Knauf H; Mutschler E; Schnippenkoetter I; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1420-5. PubMed ID: 582410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered hydroxylation rate of triamterene in patients with liver cirrhosis.
    Gundert-Remy U; Müller-Herrmann R; Mutschler E; Schäfer M; Weber E
    Int J Clin Pharmacol Ther Toxicol; 1982 Aug; 20(8):353-7. PubMed ID: 7118322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Distribution volume and elimination of triamterene and its active metabolites in the rabbit (author's transl)].
    Knauf H; Mutschler E; Wais S; Wais U
    Arzneimittelforschung; 1978; 28(8):1414-6. PubMed ID: 582408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of triamterene after i.v. administration to man: determination of bioavailability.
    Gilfrich HJ; Kremer G; Möhrke W; Mutschler E; Völger KD
    Eur J Clin Pharmacol; 1983; 25(2):237-41. PubMed ID: 6628507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of triamterene and hydrochlorothiazide and their combination in healthy volunteers.
    Möhrke W; Knauf H; Mutschler E
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):447-52. PubMed ID: 9352394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacological effects of phase-I- and phase-II-metabolites of triamterene (author's transl)].
    Knauf H; Mutschler E; Völger KD; Wais U
    Arzneimittelforschung; 1978; 28(8):1417-20. PubMed ID: 582409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of triamterene and hydroxytriamterene sulfuric acid ester on diuresis and saluresis in rats after oral and intravenous application.
    Leilich G; Knauf H; Mutschler E; Völger KD
    Arzneimittelforschung; 1980; 30(6):949-53. PubMed ID: 7191270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of triamterene and its metabolite in man.
    Hasegawa J; Lin ET; Williams RL; Sörgel F; Benet LZ
    J Pharmacokinet Biopharm; 1982 Oct; 10(5):507-23. PubMed ID: 7166735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed elimination of triamterene and its active metabolite in chronic renal failure.
    Knauf H; Möhrke W; Mutschler E
    Eur J Clin Pharmacol; 1983; 24(4):453-6. PubMed ID: 6861860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral triamterene disposition.
    Sörgel F; Hasegawa J; Lin ET; Williams RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):306-12. PubMed ID: 4028626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triamterene kinetics and dynamics in cirrhosis.
    Villeneuve JP; Rocheleau F; Raymond G
    Clin Pharmacol Ther; 1984 Jun; 35(6):831-7. PubMed ID: 6734036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of triamterene and its phase I and phase II metabolities on sodium transport of the isolated frog skin.
    Kramer HJ; Rörig M; Völger KD
    Pharmacology; 1981; 23(3):149-55. PubMed ID: 6974360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the cardiac effects of triamterene and its phase II metabolite p-hydroxytriamterene sulphuric acid ester (author's transl].
    Greeff K; Schuhmacher P
    Arzneimittelforschung; 1979; 29(4):705-6. PubMed ID: 582773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
    Fuhr U; Kober S; Zaigler M; Mutschler E; Spahn-Langguth H
    Int J Clin Pharmacol Ther; 2005 Jul; 43(7):327-34. PubMed ID: 16035375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absorption and disposition of two combination formulations of hydrochlorothiazide and triamterene: influence of age and renal function.
    Williams RL; Thornhill MD; Upton RA; Blume C; Clark TS; Lin E; Benet LZ
    Clin Pharmacol Ther; 1986 Aug; 40(2):226-32. PubMed ID: 3731685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and elimination kinetics of the combination furosemide-retard/triamterene.
    Schuster O; Loew D; Knoell HE
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):127-32. PubMed ID: 4043142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid chromatographic analysis of triamterene and its major metabolite, hydroxytriamterene sulfate, in blood, plasma, and urine.
    Sörgel F; Lin ET; Hasegawa J; Benet LZ
    J Pharm Sci; 1984 Jun; 73(6):831-3. PubMed ID: 6737274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of triamterene in the rat.
    Kau ST; Sastry BV; Alvin JD; Bush MT
    Drug Metab Dispos; 1975; 3(5):345-51. PubMed ID: 241615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.